Credit Suisse resumed coverage of Centogene with a rating of Outperform and set a new price target of $14.00

Credit Suisse reiterated coverage of Centogene with a rating of Outperform and set a new price target of $14.00 from $15.00 previously

6-K - Centogene N.V. (0001757097) (Filer)

6-K - Centogene N.V. (0001757097) (Filer)

6-K - Centogene N.V. (0001757097) (Filer)

6-K - Centogene N.V. (0001757097) (Filer)

6-K - Centogene N.V. (0001757097) (Filer)

6-K - Centogene N.V. (0001757097) (Filer)

IRANNOTICE - Centogene N.V. (0001757097) (Filer)

20-F - Centogene N.V. (0001757097) (Filer)

6-K - Centogene N.V. (0001757097) (Filer)

6-K - Centogene N.V. (0001757097) (Filer)

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has concluded its strategic review process and has entered into a Share Purchase Agreement ("SPA") pursuant to which its operating subsidiaries will be sold to an affiliate of Charme Capital Partners Limited ("Charme"), a pan-European private equity firm, for a cash purchase price of EUR 8,717,906.80. In connection with the transaction, Centogene GmbH will receive funding, secured by Saudi accounts receivables, from its Saudi Arabian

Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findingsData from over subcohort of 3,350 patients shows that the RAB32 mutation is over 100 times more prevalent in Parkinson's patients than in the general population CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data from the Company's Rostock International Parkinson's Disease (ROPAD), further supporting the association of a RAB32 gene mutation with Pa

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE'S common stock from Nasdaq. The notice indicates that CENTOGENE (the "Company") remains noncompliant with Nasdaq Listing Rule 5450(b)(2)(C), which requires a minimum USD 15 million market value of publicly held shares. Suspension of trading in the Company's common stock on Nasdaq will be effective at the open of trading on August 8

Initial data from largest international Parkinson's disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these individuals potential candidates to be included in gene-targeted trialsThe Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of Parkinson's disease (PD) to establish a better understanding of disease progression, diagnosis, and treatment for patients CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases

TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, are pleased to announce the signing of a Memorandum of Understanding (MOU) to advance drug development for lysosomal diseases (LDs) and improve the quality of life for those impacted by these conditions. The MOU outlines a strategic partnership aimed at leveraging both organizations' strengths in genetic and real-world data (RWD) to overcome barriers in dev

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company's 2024 Annual General Meeting. Shareholders voted in favor of all proposals. The shareholders extended the period for drawing up the Dutch statutory annual accounts and board report for the financial year ended December 31, 2023. The shareholders also instructed Ernst & Young Accountants LLP as the external auditor of the Company for the financial year ended December 31, 2024. In addition, the shareholders adopted t

Reported Full Year 2023 total revenues of 2% growth at €48.5 millionSecured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the PIFPositioned for strong performance in 2024, driven by new and existing Pharma business and solid Diagnostic growth in line with industry standards; guidance of FY2024 total revenue growth between 10-15%Ongoing strategic alternatives process focused on sustainable long-term value creation for the benefit of its stakeholders CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) ("we" or the "Company"), the essential life scienc

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has entered into a set of agreements with Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF) in Saudi Arabia. The expanded relationship, which takes the form of a $15 million purchase of certain of CENTOGENE's accounts receivables (AR) and an increased investment in the parties' joint venture (JV) relationship, provides funding in aggregate of approximately $20 million to CENTOGENE to support ongoing activities and to position t

CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug discovery partnership for Evotec to lead continued development. Upon Evotec exercising its option, CENTOGENE to receive an option exercise fee and other potential milestone payments and royalties CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 14, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the discovery of a new small molecule together with Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NAS

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today revealed significant growth in the CENTOGENE Biodatabank, the world's largest real-world data repository for rare and neurodegenerative diseases. Analysis of this patient data enables precise diagnosis of disease, identification of new genetic variants, and potential de-risking of drug development. The number of analyzed patient cases has grown by 13% to more than 850,000 patients as of December 31, 2023, compared to December 21, 2022, and the number of total unique varia

CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug discovery partnership for Evotec to lead continued development. Upon Evotec exercising its option, CENTOGENE to receive an option exercise fee and other potential milestone payments and royaltiesCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 14, 2024 (GLOBE NEWSWIRE) --Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the discovery of a new small molecule together with Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO). Th

Shares of Wang & Lee Group, Inc. (NASDAQ:WLGS) rose sharply in today's pre-market trading after the company reported a year-over-year increase in FY23 financial results. Wang & Lee Group posted a FY23 loss of 2 cents per share, versus a year-ago loss of 5 cents per share. The company's revenue came in at $6.83 million versus, $4.17 million in the year-ago period, according to data from Benzinga Pro. Wang & Lee Group shares jumped 37.7% to $0.7220 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Redwoods Acquisition Corp. (NASDAQ:RWOD) shares gained 141% to $17.83 in pre-market trading after falling around 3% on Thursday. Zhongchao Inc

In accordance with Listing Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company has a period of 180 calendar days from the date of notification to regain compliance with the minimum bid price requirement.

Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the extension of an ongoing partnership with Takeda (NYSE:TAK) to diagnose patients with Lysosomal Storage Disorders (LSDs). Under the renewed agreement, CENTOGENE will continue to provide Takeda with access to diagnostic testing for patients around the world. The agreement was established to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome.

CENTOGENE N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the publication in Science of research on human pre-T cell receptor alpha (pre-TCRα) deficiency, a condition that often results in infection, lymphoproliferation, and autoimmune conditions, and its effect on human immunity. The research, conducted in collaboration with the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine and researchers around the world, analyzed the function of αβ and γδ T lymphocytes, two lineages of adaptive immunity in vertebrates, in particular the essential role of the pre-TCRα chain in α

First half 2023 total revenues with double-digit growth of 15.1% at €24.6 millionBoth Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue growth between 10% to 15%Recently announced strategic collaboration with Lifera, a biopharmaceutical company wholly-owned by the Saudi Arabia Public Investment Fund (PIF), strengthens global genomic and multiomic footprint and secures CENTOGENE $30 million investment and approx. $50 million in Joint Venture upfront payment and performance-related milestones CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life s

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company's Annual General Meeting. Shareholders voted in favor of all proposals, which included the appointment of Prof. Dr. Peter Bauer as a member of the Management Board of the Company, as well as the appointment of Mary Sheahan and the reappointment of Peer Schatz as members of the Supervisory Board of the Company. The shareholders extended the period for drawing up the Dutch statutory annual accounts and board report f

Full Year 2022 total revenues with double-digit growth of 12% at €47.5 million, in line with prior guidanceSignificant expansion of gross profit margin from 32% to 42% and ongoing cost control resulted in significant improvement of net resultsBoth Pharma and Diagnostics segments positioned for strong performance in 2023, guidance of FY2023 total revenue growth between 10% to 15% CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 16, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) ("we" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022,

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the appointment of Ian Rentsch as Chief Commercial Officer and General Manager - Pharma, who will join the Company on March 15, 2023. Mr. Rentsch is a globally experienced industry leader with over 25 years of experience in the pharmaceutical and life sciences sector. He has worked with leading organizations across the globe, including IQVIA, Clinerion, AETION, VARA AI, and TriNet X – developing a comprehensive understanding of clinical development and real-world

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced unaudited financial results for the second quarter and first half ended June 30, 2022 and updated its fiscal year 2022 financial outlook. The quarterly and half year results are compared to the same periods in the prior year, unless otherwise specified, and reflect revisions as described below. Second Quarter 2022 - Financial Highlights Overall revenues increased by 21.6% year-over-year to €11.2 millionDiagnostics segment revenues increased by 18.3% year-over-ye

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the appointment of Mary Sheahan as a member of the Supervisory Board, to be confirmed at the Company's next General Meeting of Shareholders. Ms. Sheahan will serve as a member ad interim of the Company's Supervisory Board starting December 1, 2022. It is also planned that Ms. Sheahan will assume the role of Chair of the Audit Committee. Ms. Sheahan brings over 20 years of experience in private and publicly listed international pharmaceutical and life science c

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, today announced the voting results of the Company's Annual General Meeting. Shareholders voted in favor of all proposals, which included the appointment of Miguel Coego Rios as Managing Director and Chief Financial Officer. The shareholders adopted the Dutch statutory annual accounts for the financial year ended December 31, 2021, and approved the discharge from liability for the members of the Management and Supervisory Boards with respect to the 2021 financial year. Also app

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, today announced the appointment of Miguel Coego Rios as Managing Director and Chief Financial Officer of the Company, effective June 22, 2022. "As we continue to make progress on pivoting the organization to focus on Core Business execution, we are very fortunate to have someone of Miguel's caliber and extensive experience to contribute to our financial leadership and success. With more than a decade of experience in senior finance roles in the biopharma sector, he will be

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced plans for the transition of Chief Financial Officer René Just and the appointment of Miguel Coego Rios as Executive Vice President of Finance & Legal and Interim CFO. René Just has resigned from the Company effective March 31, 2022, after the expected filing date of CENTOGENE's Annual Report on Form 20-F. Miguel Coego Rios will join the Company on February 08, 2022, and work closely through the transition with current Chief Financial Officer R

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the Company's Supervisory Board's nomination of Kim Stratton as Chief Executive Officer, transitioning from her prior designation as Interim CEO. In her role as CEO, Mrs. Stratton will now lead CENTOGENE's ongoing important strategic evolution on its path to maximizing stakeholder value creation. Kim Stratton commented, "I am excited to continue my journey at CENTOGENE and officially take on the role of Chief Executive Officer. I have known a